Russia To Fund $4 Million Trials Of Cleveland BioLabs Stem Cell Booster
This article was originally published in PharmAsia News
Russia’s Ministry of Industry and Trade reached a $4 million agreement with U.S.-based Cleveland BioLabs to form an alliance to develop a drug intended to stimulate the growth of stem cells.
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.